KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Amortization of Deferred Charges (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Amortization of Deferred Charges data on record, last reported at $2.7 million in Q4 2025.

  • For Q4 2025, Amortization of Deferred Charges rose 135.34% year-over-year to $2.7 million; the TTM value through Dec 2025 reached $11.0 million, up 4558.9%, while the annual FY2025 figure was $11.0 million, 4558.9% up from the prior year.
  • Amortization of Deferred Charges reached $2.7 million in Q4 2025 per AQST's latest filing, roughly flat from $2.7 million in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $2.8 million in Q1 2025 and bottomed at -$7.8 million in Q4 2024.
  • Average Amortization of Deferred Charges over 5 years is $769850.0, with a median of $674000.0 recorded in 2021.
  • The widest YoY moves for Amortization of Deferred Charges: up 5910.87% in 2024, down 17010.87% in 2024.
  • A 5-year view of Amortization of Deferred Charges shows it stood at $127000.0 in 2021, then plummeted by 54.33% to $58000.0 in 2022, then fell by 20.69% to $46000.0 in 2023, then crashed by 17010.87% to -$7.8 million in 2024, then soared by 135.34% to $2.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Amortization of Deferred Charges were $2.7 million in Q4 2025, $2.7 million in Q3 2025, and $2.7 million in Q2 2025.